• JACC - Outpatient Worsening Heart Failure in Patients with ATTR CM in the HELIOS-B Trial | JACC | AHA 2024

  • Nov 20 2024
  • Length: 11 mins
  • Podcast

JACC - Outpatient Worsening Heart Failure in Patients with ATTR CM in the HELIOS-B Trial | JACC | AHA 2024

Listen for free

View show details

  • Summary

  • JACC: Associate Editor Michelle M. Kittleson, MD, PhD, FACC, talks with authors Scott Solomon, MD, FACC and. Marianna Fontana, MD, about their study published in JACC and presented at AHA. Outpatient worsening heart failure (HF) (oral diuretic intensification or initiation) is simple to assess and has been shown to be prognostic of mortality in patients with ATTR-CM. In this pre-specified analysis of a contemporary ATTR-CM population, patients with outpatient worsening HF had an increased risk of all-cause mortality and CV events and all-cause mortality, as well as greater deterioration in assessments of functional capacity, health status, and quality of life. Vutrisiran significantly reduced the risk of outpatient worsening HF and the composite of outpatient worsening HF, all-cause mortality, and recurrent CV events compared with placebo.
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about JACC - Outpatient Worsening Heart Failure in Patients with ATTR CM in the HELIOS-B Trial | JACC | AHA 2024

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available